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IRCBACKGROUND Anderson-Fabry disease (AFD) is a rare X-linked lysosomal storage disease, caused by defects of the
alpha-galactosidase A (GLA) gene. AFD can affect the heart, brain, kidney, eye, skin, peripheral nerves, and gastroin-
testinal tract. Cardiology (hypertrophic cardiomyopathy), neurology (cryptogenic stroke), and nephrology (end-stage
renal failure) screening studies suggest the prevalence of GLA variants is 0.62%, with diagnosis confirmation in 0.12%.
OBJECTIVES This study sought to expand screening from these settings to include ophthalmology, dermatology,
gastroenterology, internal medicine, pediatrics, and medical genetics to increase diagnostic yield and comprehensively
evaluate organ involvement in AFD patients.
METHODS In a 10-year prospective multidisciplinary, multicenter study, we expanded clinical, genetic, and biochemical
screening to consecutive patients enrolled from all aforementioned clinical settings. We tested the GLA gene and
a-galactosidase A activity in plasma and leukocytes. Inclusion criteria comprised phenotypical traits and absence of
male-to-male transmission. Screening was extended to relatives of probands harboring GLA mutations.
RESULTS Of 2,034 probands fulfilling inclusion criteria, 37 (1.8%) were carriers of GLA mutations. Cascade family
screening identified 60 affected relatives; clinical data were available for 4 affected obligate carriers. Activity of
a-galactosidase A in plasma and leukocytes was diagnostic in male subjects, but not in female subjects. Of the 101 family
members harboring mutations, 86 were affected, 10 were young healthy carriers, and 5 refused clinical evaluation. In the
86 patients, involved organs or organ systems included the heart (69%), peripheral nerves (46%), kidney (45%), eye
(37%), brain (34%), skin (32%), gastrointestinal tract (31%), and auditory system (19%). Globotriaosylceramide accu-
mulated in organ-specific and non-organ-specific cells in atypical and classic variants, respectively.
CONCLUSIONS Screening probands with clinically suspected AFD significantly increased diagnostic yield. The heart
was the organ most commonly involved, independent of the clinical setting in which the patient was first evaluated.
(J Am Coll Cardiol 2016;68:1037–50) © 2016 by the American College of Cardiology Foundation.m the aCenter for Inherited Cardiovascular Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation
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1038A nderson-Fabry disease (AFD) is anX-linked disorder caused by defi-ciency of the lysosomal enzyme
a-galactosidase A (a-Gal) (1), resulting in
intracellular accumulation of globotriaosyl-
ceramide (Gb3) and multiorgan system dam-
age. AFD prevalence at birth ranges between
1 in 40,000 and 1 in 110,000, based on level
of a-Gal activity (1–3). The diagnosis most
often results from screening large series of
patients with phenotypic traits commonly
observed in AFD (4–6). In a recent systematic
review of screening studies of high-risk pop-
ulations, the overall prevalence of individ-
uals with alpha-galactosidase A (GLA) genevariants was 0.62% (including genetic variants of un-
known significance); prevalence of a definitive diag-
nosis was 0.12% (7).SEE PAGE 1051Often associated with a delayed diagnosis, AFD is
otherwise characterized by variability in age of onset,
phenotype (including the early, severe classic phe-
notypes as well as the later, more mild presentation)
(3), and phenotype among carriers of the same mu-
tations within families (3,8,9). Male subjects with the
classic form of AFD and low or absent enzymatic ac-
tivity develop early signs and symptoms in childhood
or adolescence (acroparesthesias/neuropathic pain,
angiokeratomas, gastrointestinal symptoms, corneal
opacities) (10). Vascular complications, renal failure,
thickening of the left ventricular (LV) walls
mimicking sarcomeric hypertrophic cardiomyopathy
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received May 18, 2016; accepted May 19, 2016.attack (TIA) are features that may occur in adults
(4–6,8). Patients with atypical variants may develop
late-onset renal failure, left ventricular hypertrophy
(LVH), cerebrovascular disease, or a combination
thereof (3,11). Female subjects experience later onset
of disease and, typically, exhibit heterogeneous and
milder phenotypes (3,8,9,11). The residual enzyme
activity in female heterozygotes may be normal,
limiting the role of ascertaining a-Gal activity (12–14).
Thus, genetic testing is necessary to confirm the
diagnosis in female subjects. The integrated pheno-
typic and genetic diagnosis provides the basis for
enzyme replacement therapy, though evidence-based
clinical benefits when the heart, kidney, and brain are
involved are limited by low numbers of randomized
controlled trials (15).
Our study was designed to screen patients from all
clinical settings pertinent to AFD to increase the yield
of diagnoses of AFD in high-risk cohorts of patients
presenting with different but relevant phenotypic
traits (isolated or combined) and accurately describe
organ involvement in patients/relatives (16).
METHODS
In 2004, we established a prospective multidisci-
plinary and multicenter study, evaluating patients
with a high degree of suspicion for AFD presenting to
cardiology, neurology, nephrology, pediatrics,
ophthalmology, dermatology, gastroenterology, in-
ternal medicine, and genetics clinics. These patients
underwent comprehensive clinical evaluation, ge-
netic counseling, pathologic analysis, and cascade
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1039activity assays and genetic testing were centralized in
2 core labs, 1 for the former (overseen by M.M.) and 1
for the latter (overseen by E.Ar.). Clinical evaluation
included the following: physical examination to
assess overt traits such as “Fabry face” and angio-
keratomas; cardiological work-up with visit, electro-
cardiography, echocardiography, and cardiac
magnetic resonance imaging (when accepted and
possible); neurologic evaluation with magnetic reso-
nance imaging, according to the neurologist’s in-
dications; nephrology evaluation, and related
biochemical and imaging investigation in patients
with otherwise unexplained proteinuria, increased
urinary albumin excretion, abnormal glomerular
filtration rate, and estimated glomerular filtration
rate, up to severe chronic renal failure; ophthalmo-
logic evaluation for corneal deposits and other traits
associated with AFD (e.g., retinal vessel tortuosity
and cataracts); pediatric evaluation in children with
acroparesthesia/neuropathic pain, gastrointestinal
disturbances after exclusion of diseases such as celiac
disease and inflammatory bowed disease; dermato-
logic visit with dermoscopy and biopsy, when needed
or feasible, of skin lesions; and psychological support,
when accepted, by patients or their relatives.
The project was approved by the ethical commit-
tees of all participating centers. Each specialist
participating in the project proceeded with multidis-
ciplinary evaluation upon identifying a tell-tale clin-
ical trait suggestive of AFD. Table 1 shows major
inclusion criteria based on organ system (details in
the Online Appendix). A web-assisted database was
developed to collect clinical information. Family
screening was offered to all relatives of probands,
including clinical and imaging evaluation, as well asTABLE 1 Clinical Criteria for Enrollment
Clinical Setting n Age (yrs)
Mutated
Probands
Neurology 1,323 48 (40–55) 17 (1.28) Crypto
Cardiology 473 46 (33–59) 8 (1.69) HCM, c
Nephrology 72 51.5 (46–64) 2 (2.7) Chroni
Ophthalmology 23 43 (35–51) 3 (13) Noniat




47 45 (36–53) 3 (6.3) Gastro
Medical genetics 28 40 (39–53) 2 (7.1) Multio
X-l
Dermatology 27 45 (37–53) 0 Presen
are
Values are n, median (interquartile range), or n (%). *Exclusion of most common causes
AFD ¼ Anderson-Fabry disease; CD ¼ Crohn’s disease; HCM ¼ hypertrophic cardiom
hypertrophy; TIA ¼ transient ischemic attack; WML ¼ white matter lesions.genetic testing and determination of enzyme level
assay. We used the MOGE(S) (morphofunctional, or-
gan involvement, genetic or familial, etiology, stage)
classification system (16) for genotype/phenotype
description.
GENETIC TESTS AND ASSAYS. We sequenced coding
and flanking regions of the GLA gene (Online
Appendix) and performed multiple ligation-
dependent probe amplification in male patients who
demonstrated low a-Gal activity in plasma or gran-
ulocytes but tested normal at sequencing. The anal-
ysis included intronic haplotypes potentially
associated with decreased enzyme activity (17). The
IVS4þ919 G>A mutation that has been reported as
common in late onset Chinese and Taiwanese AFD
patients (18,19) was investigated by sequencing using
specific primers. Mutations and variants of unknown
significance have been defined according to guide-
lines (20); criteria are in the Online Appendix.
In 8 patients with LVH (>15 mm), we additionally
sequenced the HCM gene panel to exclude the
concomitant, coincidental presence of 2 different
genetic diseases. In patients with cryptogenic stroke
or TIA and carriers of the p.(Asp313Tyr) variant, we
sequenced the mitochondrial deoxyribonucleic acid
region encompassing MT-TL1 and MT-RNR2 genes
commonly associated with MELAS (mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like
episodes) syndrome mutations (21).
We assessed a-Gal activity in blood plasma and
peripheral blood leukocytes using fluorimetry and
4-methylumbelliferyl–a-D-galactopyranoside as a
substrate in the presence of N-acetylgalactosamine
(Online Appendix). We generated standards forInclusion Criteria / Common to All Disciplines*
genic stroke, TIA, migraine with/without aura with imaging showing WML
oncentric mild LVH, no LV outflow tract obstruction
c renal failure; proteinuria, increased urinary albumin excretion
rogenic cornea verticillata, juvenile cataract, retinal vessel tortuosity
inal crises of pain with diarrhea after exclusion of CD and IBD;
oparesthesias/neuropathic pain, heat intolerance
intestinal and multiorgan/tissue disturbances/involvement
rgan/tissue involvement suspected for AFD with evaluation of possible
inked transmission in family pedigrees
ce of angiokeratomas not exclusively located in typical “bathing suit”
as; labial and proximal nail fold telangiectasia
of similar phenotypes and of probands from families with male-to-male transmission.
yopathy; IBD ¼ irritable bowel disease; LV ¼ left ventricular; LVH ¼ left ventricular
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1040reference values of plasma and granulocyte a-Gal
activity in a control group in accordance with the
Standards for Reporting of Diagnostic Accuracy (22).
TISSUE BIOPSY AND IN VITRO CELLULAR STUDIES.
We performed tissue biopsies to evaluate intracellular
accumulation of Gb3. Anti-a-Gal and anti-Gb3 (CD77)
antibodies were used for immunohistochemical
studies, both by light and electron microscopy. Tissue
biopsies were performed in mutation carriers with
low a-Gal levels as follows: patients carrying novel
mutations and patients with very mild LVH (#13 mm)
before deciding about enzyme replacement therapy
administration; patients with symptoms such as se-
vere gastrointestinal disturbances to exclude comor-
bidities; and patients with severe LVH to confirm Gb3
accumulation. In patients with predominant neuro-
logic traits (stroke, TIA), we could not perform brain
biopsy, and determination of organ involvement was
imaging based. We therefore generated cell cultures
from circulating peripheral blood mononuclear cells
(PBMC) to test the presence of a-Gal and Gb3
(Online Appendix). In fact, recent guidelines for
investigating causality of sequence variants in human
disease indicate the need of experimental validation
of the predicted damaging impact of candidate vari-
ants using assays of patient-derived tissue or well-
established cell systems (23).
STATISTICAL ANALYSIS. Descriptive statistics were
computed as median and interquartile range for
continuous variables and as counts and percentages
for categorical variables. We used Mann-Whitney U
tests for continuous variables and Fisher and chi-
square tests for categorical variables. A p value <0.05
was considered statistically significant. MEDCALC
(version 14.10.2, MedCalc Software, Ostend, Belgium)
was used for statistical evaluation. Receiver-
operating characteristic analysis was used to find
optimal thresholds for plasma and leukocytes in both
male and female carriers versus noncarriers of mu-
tations. Receiver-operating characteristic areas under
the curve were calculated as a measure of diagnostic
performance, with differences calculated and tested
according to the methods of Hanley and McNeil (24).
We used cutoff points that maximized both sensi-
tivity and specificity (25).
RESULTS
We enrolled 2,034 consecutive probands who pre-
sented with 1 or more clinical traits typically associ-
ated with AFD, after excluding known causes of the
same traits (Table 1, Central Illustration).
We identified GLA mutations in 37 of 2,034 pro-
bands (1.8%) including 19 male and 18 female patients(Online Table 1). Excluding the 8 proband carriers of
the debated pseudodeficiency variant p.(Asp313Asn)
and the carrier of the novel p.(Gln57Arg), the preva-
lence was 1.3%. Overall, 133 relatives of 37 probands
underwent clinical and genetic screening, 60 of
whom were mutation carriers. We obtained detailed
clinical information for 4 obligate carriers. Multiple
ligation-dependent probe amplification in 135 cases
with plasma enzyme activity in the low to normal
ranges did not show large gene rearrangements.
Haplotypes I to IV that were reported as being asso-
ciated with decreased enzyme activity levels (11) were
found in 517 of 2,034 patients and did not show sig-
nificant association with enzyme plasma levels when
compared with cases without the same haplotypes
(Online Table 2). Novel, unique intronic, synony-
mous, and missense variants are reported in Online
Table 3. The Taiwanese-Chinese IVS4þ919 G>A mu-
tation (18,19) was not seen in our series. Sequencing
of the HCM genes in 8 patients with LVH >15 mm
identified known and novel genetic variants of un-
known significance (Online Table 3), in presence of
substantial tissue accumulation of Gb3 GLA
p.(Phe113Leu), n ¼ 1 (Online Figure 1); p.(Tyr184Asp),
n ¼ 1; and p.(Asn215Ser), n ¼ 4], in absence of segre-
gation of the HCM variant with the cardiac phenotype
in the family [GLA p.(Gln57Arg)], and in a boy with
classic AFD and carrier of the GLA p.(Phe337Ser).
Plasma a-Gal activity measurements were available
in 1,501 consecutive probands (714 were female, 787
male) of the 2,034 genetically screened probands.
Leukocyte a-Gal assay results were available in 865
probands (421 were female, 444 male). Plasma me-
dian values were similar in male and female subjects
who did not carry GLA mutations (Figures 1A and 1B),
lower and diagnostic in male carriers of mutations,
but lower and nondiagnostic in female subjects with
GLA mutations (Online Table 4). The specificity,
sensitivity, and area under the curve are presented in
Figures 1C to 1F.
ORGANS, TISSUES, AND CELLS. Organ system involve-
ment was assessed in a multidisciplinary context.
Application of the MOGE(S) system displayed the
clinical profile (Online Table 5): 62 of 96 mutation
carriers (65%) demonstrated multiple organ involve-
ment; 23 (24%) had 1 organ involvement only; 1
(1%) complained of acroparesthesias; 10 (10%) were
healthy carriers. For 5 of 101 mutation carriers, we
were unable to perform multidisciplinary evaluation
(Table 2).
We performed tissue biopsies in 17 patients
(endomyocardial in 6, gastric in 1, skin in 10). Light
and electron microscopy of the endomyocardial bi-
opsy demonstrated intracellular Gb3 deposits in
CENTRAL ILLUSTRATION Screening for AFD


































1.28%   of screened patients were carriers of GLA mutations
Favalli, V. et al. J Am Coll Cardiol. 2016;68(10):1037–50.
This study was designed to demonstrate that screening high-risk patients from multiple clinical settings could increase the diagnostic yield for Anderson-Fabry disease
(AFD). Of the 8 clinical fields pertinent to AFD included, all produced positive cases except dermatology. In the 86 affected family members, the heart was the organ
with highest involvement.
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1041cardiac and classic AFD (Figures 2A and 2B). Immu-
nohistochemistry with anti-Gb3 antibodies demon-
strated specific immunostaining of the deposits
(Figures 2C and 2D). In classic AFD, skin biopsies
demonstrated Gb3 deposits in vascular and nonvas-
cular smooth muscle cells, dermal fibroblasts, adipo-
cytes, and endothelial cells (Figures 3A to 3E); myelin
sheaths of sensitive neurons showed degenerative
features (Figure 3F). However, skin biopsies failed to
demonstrate significant Gb3 accumulation in carriers
of GLA cardiac variants (Online Figures 2 and 3).Gastric biopsy in a carrier of the p.(Ser401X) mutation
showed positive anti-Gb3 immunostain in vascular
smooth muscle cells and endothelia as well as inter-
stitial cells (Figure 4). Immunostain with anti-a-Gal
and anti-CD77 antibodies demonstrated attenuated
and normal expression of the enzyme in classic and
atypical forms, respectively (Figure 5A), and Gb3
presence (Figure 5B) in cultured PBMC from patients
with atypical variants.
The GLA p.(Asp313Tyr) pseudodeficiency allele
was classified as a genetic variant of unknown
FIGURE 1 Plasma and Leukocytes Enzyme Activity in Probands



































































































































In assays of a-galactosidase A (a-Gal) plasma activity (A) in 1,501 tested probands and a-Gal leukocyte activity (B) in 865 probands, enzyme
activity level in mutated probands was significantly lower than in nonmutated probands. Receiver-operating characteristic analysis in male
subjects (C) and female subjects (D) established the cutoff values of a-Gal activity in plasma with better ratios between sensitivity and sen-
sibility (3.5 nmol/ml/h in male subjects; 5.7 nmol/ml/h in female subjects). The specificity and sensitivity values confirmed enzyme activity to be
a more reliable biomarker in male subjects. Receiver-operating characteristic analysis in male subjects (E) and female subjects (F) established
the cutoff value of a-Gal activity in leukocytes with better ratios between sensitivity and sensibility (10.95 nmol/ml/h in male subjects; 15.5
nmol/ml/h in female subjects). AUC ¼ area under the curve; GLA ¼ alpha-galactosidase A gene; WT ¼ nonmutated.
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Clinically affected 37 49 (including 4 OC) 86
HC 0 10 10
Clinical data available 37 59 96





Heart 28 31 59
LVH >13 mm 24 19 43
With AVB (9) (2) (11)
LVH 11–13 mm (early) 4 12 16
With AVB (1) (1)
No cardiac involvement or ECG
signs only
9 28 37
Short PR interval as only marker
(without LVH)
2 4 6
No involvement 7 24 (including 10 HC) 31
Kidney 20 19 39
Dialysis 3 3
Kidney transplantation 1 1
Severe CRF 2 6 8
Increased urinary albumin excretion,
proteinuria, increased creatinine,
decreased eGFR, increased GFR
14 13 27
Brain 23 6 29
Stroke 14 3 17
TIA 4 1 5
WML (imaging screening) 7 2 9




Gastroenteric system 11 16 27
Eye 15 17 32
Corneal deposits 14 17 31
Corneal deposits and retinal artery
thrombosis
1 1
Skin (angiokeratomas) 16 12 28
Peripheral nerves (acroparesthesias) 18 22 40
Auditory system 9 7 16
Comorbidities
HPN 10 15 25
HPN þ diabetes 1 1
HPN þ IHD 1 1
Patent foramen ovale 2 2
Phenylketonuria 1 1
Nephrectomy for hydronephrosis 1 1
Celiac disease þ gastric lymphoma 1 1
Cancer (colorectal) 1 1
Cancer (tongue) 1 1
Rheumatoid arthritis 1 1
Acoustic neuroma 1 1
Dyslipidemia 2 1 3
Total comorbidities 20 19 39
*Number of relatives ¼ 60 þ 4 OC ¼ 64. †Independently of the screening setting, in 86 patients with $1 trait of
the disease (up to 7).
AVB ¼ atrioventricular block; CRF ¼ chronic renal failure; ECG ¼ electrocardiogram; eGFR ¼ estimated
glomerular filtration rate; GFR ¼ glomerular filtration rate; HC ¼ healthy carrier; HPN ¼ hypertension; IHD ¼
ischemic heart disease; OC ¼ obligate carriers; other abbreviations as in Table 1.
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1043significance (Online Table 5). The 8 probands who
carried this variant were included in the screening
for brain involvement. Data regarding plasma
enzyme activity in probands and relatives are in the
Online Appendix. Of the 8 probands in this group, 6
had a stroke, 1 had a TIA, and 1 had migraine with
aura, the latter 2 with magnetic resonance–verified
white matter lesions (WML); 6 probands also
showed additional traits. Of the 17 relatives with
GLA p.(Arg313Tyr), 6 showed involvement of more
than 1 organ, 4 showed involvement of 1 organ, 3
were healthy carriers, and 4 did not proceed with
multidisciplinary evaluation. Six probands and 5
relatives were carriers of the mitochondrial deoxy-
ribonucleic acid 3010G>A mutation in the MT-RNR2,
a common single nucleotide polymorphism that is
also associated with cyclic vomiting syndrome with
migraine.
The GLA p.(Asn215Ser) cardiac variant was iden-
tified in 5 probands referred from cardiology in the
setting of HCM. Carriers of this mutation showed
low plasma enzyme activity (Online Appendix) and
severe Gb3 accumulation in myocytes (Figure 2). Skin
biopsies in 3 patients were noninformative, nonsig-
nificant, or showed focal intracellular Gb3 accumu-
lation similar to that observed in skin biopsies
of carriers of the p.(Asp313Tyr) variant (Online
Figure 3), respectively. Cultured peripheral mono-
nuclear cells demonstrated normal enzyme expres-
sion and Gb3 accumulation in male and female
subjects.
DISCUSSION
In this study, we found that genetic screening of high-
risk populations selected in the context of multi-
specialty clinics provided an overall higher yield of
diagnoses [1.8% and 1.3% excluding probands with
p.(Asp313Tyr) and p.(Gln57Arg)] than that achieved
by screening large series of patients with HCM,
cryptogenic stroke, or end-stage renal failure
(4–7,26–28). The incremental rate of detection of AFD
in our series compared with prevalence data reported
to date in selected cardiology, neurology, or
nephrology settings was thus likely explained by the
contribution of patient evaluations being performed
in multiple clinical settings. Selection of patients
without evidence of male-to-male transmission of the
trait in the family might also have contributed.
Ophthalmologic evaluation/involvement was found
to be very important: 3 of 3 patients enrolled because
of noniatrogenic cornea verticillata tested positive for
GLA mutations, whereas 20 patients enrolled because
of vessel tortuosity and/or cataracts tested negative.
FIGURE 2 Endomyocardial Biopsies in Cardiac and Classic AFD
Mutations seen in endomyocardial biopsies from patients include the following: (A) a hematoxylin and eosin stain sample from a male carrier of
the p.(Asn215Ser) mutation in which the optically empty myocytes constitute a typical light microscopy marker of intracellular storage;
(B) electron micrograph showing typical osmiophilic bodies in the endomyocardial biopsies of a female carrier of the p.(Tyr184Asp) mutation;
(C) light immuno-microscopy of EMB samples from a young male carrier’s of the p.(Asn215Ser) mutation demonstrating early hypertrophic
cardiomyopathy; and (D) electron immuno-microscopy of EMB sample from a male patient carrier of the p.(Phe113Leu). AFD ¼ Anderson-Fabry
disease; EMB ¼ endomyocardial biopsy.
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1044This supported evidence from other recent reports
(29,30), in which noniatrogenic cornea verticillata
was a highly specific clinical marker.
Whereas severity scores showed that heart, kidney,
and brain involvement are the major prognostic de-
terminants (31,32) in AFD, diagnostic scoring systems
could better take advantage of objective markers of
high diagnostic specificity, regardless of clinical rele-
vance. Traits such as acroparesthesias (33) or abdom-
inal crises (3) are subjectively described, and thus
challenging to ascribe to AFD. Differential diagnosis in
adults includes systemic amyloidosis with peripheral
neuropathy in patients with cardiac and renal
involvement. In children, the recurrence of abdominal
crises and acroneuropathic pain triggered by heat or
fever increases clinical suspicion. Concomitant clini-
cally overt involvement of the heart, kidneys, and
brain, which may contribute to the clinical suspicion,
does not necessarily recur in all patients, especiallythose with cardiac, renal, or nervous GLA variants.
Mitochondrial diseases, such as MELAS, might show
concentric HCM that typically evolved through late
ventricular dilation and dysfunction, renal failure that
may necessitate hemodialysis, and recurrent crypto-
genic stroke, but they might also demonstrate ocular
traits that do not include corneal deposits. Diffuse
angiokeratomas rarely bring a patient to clinical
attention. Phenotype heterogeneity within families
demonstrating classic forms of AFD or involvement of
the same organ in those carrying atypical GLA variants
might contribute to clinical suspicion. Overall, pa-
tients with AFD should be evaluated as a whole, and
within the context of family history, independent of
the predominant organ involved, a strategy requiring
a disease-oriented diagnostic mindset. The MOGE(S)
nosology was recently generated to precisely describe
the genotype-phenotype in cardiomyopathies (16)
(Online Table 5).
FIGURE 3 Skin Biopsy in AFD
Electron micrographs of a skin biopsy sample from a male patient carrier of the p.Ala292_Met296del mutation show globotriaosylceramide
accumulation in (A) nonvascular smooth muscle cells; (B) endothelial cells; (C) dermal fibroblasts; (D) vascular smooth muscle cells;
and (E) adipocytes. (F) This sensory cutaneous nerve shows degenerative features. AFD ¼ Anderson-Fabry disease.
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1045DIAGNOSIS OF AFD. Definitive diagnosis should rely
on genetic testing, enzyme activity, and tissue
studies demonstrating intracellular Gb3 accumula-
tion. Absent pathological evaluation, interpretation
of genetic testing results is supported by enzyme as-
says in male subjects and by imaging or functional
tests sufficient to demonstrate tissue involvement
otherwise. Confirmed pathologic mutations overall
are sufficient for the diagnosis. For novel mutationsor atypical or provisional variants, in silico analyses
might contribute, but are not conclusive: a typical
example is p.(Asn215Ser), which is benign in silico but
associated with severe intramyocyte accumulation of
Gb3; or conversely, p.(Asp313Tyr), which is damaging
in silico but considered to be a genetic variant of
unknown significance or single nucleotide poly-
morphism. Recently, p.(Arg118Cys), originally inter-
preted as pathologic, has been reported as a variant
FIGURE 4 Gastric Biopsy in AFD
(A) Low magnification view of the gastric biopsy from a young male patient carrier of the p.(Ser401X); the patient complained of severe
gastrointestinal symptoms, with epigastric pain crises, and acroneuropathic pain during febrile episodes. Antiglobotriaosylceramide immu-
nostain of vascular smooth muscle cells and endothelia (insets: dashed line ¼ C; solid line ¼ D) as well as interstitial cells. (B) Negatively
immunostained gastric biopsy of a patient with gastrointestinal symptoms and carrier of the p.(Asp313Tyr). AFD ¼ Anderson-Fabry disease.
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1046not causing an AFD phenotype (34). The pathogenic
roles of p.(Ala143Thr), p.(Ser126Gly), p.(Arg112His),
p.(Pro60Leu), and p.(Glu66Gln) have been ques-
tioned on the basis of tissue studies and Gb3 dosage
(35–38). These examples highlight the need for inte-
grated interpretation of genetic data based on precise
evidence or reasons for exclusion. As an example, ifthe above-mentioned variants were confirmed as be-
ing nonpathogenic, published prevalence data would
likely vary.
Tissue studies, when feasible, demonstrate
Gb3 storage. Conventional light microscopy shows
optically empty cells; ultrastructural hallmarks
are the typical osmiophilic lamellar bodies; and
FIGURE 5 In Vitro Study of AFD
(A) Cultured peripheral blood mononuclear cells immunostained with anti-a-Gal antibody from patients carriers of the p.(Asn215Ser),
p.(Phe113Leu), p.(Asp313Tyr) and p.Tyr184Asp mutation showed immunostaining similar to that of cells from control subjects (Ctrl). (B) In
cultured peripheral blood mononuclear cells of 3 patient carriers of p.(Phe113Leu), p.(Arg215Ser), and p.(Asp313Tyr), green particles indicated
anti-Gb3 immunoreactivity, which is highly represented in the 3 cell lines. DAPI ¼ 4’,6-diamidino-2-phenylindole; Gb3¼ globotriaosylceramide;
other abbreviations as in Figures 1 and 3.
J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6 Favalli et al.
S E P T E M B E R 6 , 2 0 1 6 : 1 0 3 7 – 5 0 Genetic Screening of Anderson-Fabry Disease
1047
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: A
rare, lysosomal disease, AFD affects multiple organ
systems. Precise diagnosis is essential for the effective
enzyme replacement therapy administration. The
heart is the most commonly involved organ, regard-
less of the clinical setting in which the patient pre-
sents, but screening patients in ophthalmology,
dermatology, gastroenterology, internal medicine,
pediatrics, and medical genetics clinics in addition to
high-risk patients in cardiology (HCM), neurology
(cryptogenic stroke, TIA, and migraine), and
nephrology (end-stage renal failure) clinics for de-
fects in the GLA gene, increases the diagnostic yield.
TRANSLATIONAL OUTLOOK: Future AFD studies
could benefit from use of the MOGE(S) nosology
system to provide patient-specific description of
multiorgan involvement, inheritance pattern, and the
associated mutation.
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specific labeling with anti-Gb3 antibodies. Our results
supported a tissue-specific, mutation-dependent
“affinity” for Gb3 storage and contributed to
explaining the cardiac, renal, and, probably, neuro-
logic variants: in fact, Gb3 accumulated in myocytes
but not in skin or vascular cells of patients who carry
the cardiac variants [i.e., p.(Asn215Ser) and
p.(Phe113Ser)]. However, classic, juvenile, and sys-
temic forms have typically demonstrated involve-
ment of interstitial and vascular smooth muscle cells
[p.(Ala292_Met296del) in skin; p.(Ser401X) in gastric
tissue] (Figures 3 and 4). Therefore, skin biopsy is
useful in patients with classic AFD but useless in
atypical variants (Online Figures 2 and 3). In cultured
PBMC from carriers of atypical cardiac variants, the
immunohistochemical expression of a-Gal was
normal, confirming a functional impairment rather
than decreased enzyme expression; the paradigmatic
example is p.(Asn215Ser), which causes the loss of a-
Gal glycosylation at site 3, which is essential for
enzyme solubility (39).
In our experience, the issue of the pseudodefi-
ciency allele p.(Asp313Tyr) requires further discus-
sion: all 8 probands in our series were from
neurologic settings; 7 also showed extraneurologic
traits. Skin biopsies, similar to those in cardiac vari-
ants, were not diagnostically helpful. Brain biopsies
are not possible, although imaging demonstrated
tissue and vascular pathology. Autopsy or other
pathologic evaluations do not exist. Family segrega-
tion studies (Online Figure 4) and in silico analysis do
not help, based on both past in vitro studies demon-
strating 60% of wild-type enzyme activity in vitro
(40,41) and identification of 3 patients with a second
GLA mutation (42,43). Based on our data, the
p.(Asp313Tyr) variant recurs in patients presenting
with cryptogenic stroke, TIA, WML identified by im-
aging, and migraine with aura associated with WML.
Cultured PBMC from mutation carriers showed fea-
tures similar to those from carriers of confirmed
pathologic mutations. Evidence, both for (44–46) and
against (41,43), was nonconclusive for unambiguous
assignment of disease causality or contribution for
this variant. In the large family reported by Lenders
et al. (46), all 7 mutation carriers had WML but 2
noncarriers did not. Neurologists face the difficult
role of managing these patients and excluding with
certainty this variant’s contribution to the complex
neurological spectrum of signs/symptoms observed.
STUDY LIMITATIONS. Our study was designed more
than 10 years ago and did not include data on Gb3 and
Lyso-Gb3, which is emerging as a sensitive diagnosticmarker. The different prevalence of traits mimicking
cardiac, neurologic, and renal disease (seen in AFD) in
the general population may help to explain the dif-
ferences in numbers of cases enrolled per discipline.
CONCLUSIONS
Expanded screening of high-risk populations from the
cardiology, neurology, and nephrology settings to
ophthalmology, gastroenterology, internal medicine,
pediatrics, dermatology, and medical genetics
increased the yield of diagnosis of AFD. The heart was
the most commonly involved organ, regardless of the
clinical setting in which the patient was first evalu-
ated. Traits contributing to the diagnosis differed
from those impacting prognosis, including non-
iatrogenic cornea verticillata. Pathologic analysis
confirmed disease-causing mutations and also
contributed to unraveling the role of novel and pro-
visional variants identified in the past. The system-
atic annotation of key genotype-phenotype data,
such as with the MOGE(S) nosology system, helped to
collect precise clinical and genetic data for future
studies.
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